Facing the COVID-19 global healthcare crisis, scientists worldwide are collaborating to
develop prophylactic and therapeutic interventions against the disease. Antibody …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of
SARS-CoV-2 variants raised concerns about these therapies' efficacy and long-term …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Researchers from the world over are working to create prophylactic and therapeutic
interventions to combat the COVID-19 global healthcare crisis. The current therapeutic …

The world is facing up the most considerable vaccination effort in history to end the
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …

The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis …

With the recent spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) _
infecting> 16 million people worldwide as of 28 July 2020, causing> 650 000 deaths, there …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …